Contract 75A50126F61020
Glaxosmithkline, Llc · Department Of Health And Human Services · March 30, 2026
Glaxosmithkline, Llc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on March 30, 2026 for $493,000 of work in research and development in biotechnology (except nanobiotechnology). Performance is in Durham, NC. This is a task or delivery order issued under parent IDIQ 75A50122D00002. It uses firm fixed-price contract pricing.
Contract details
- PIID
- 75A50126F61020
- Parent IDIQ
- 75A50122D00002
- Award type
- Delivery Order
- Pricing
- Firm Fixed Price
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- Drugs And Biologicals
- Place of performance
- Durham, NC
- First action
- March 30, 2026
Description
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN
Modification timeline
-
March 30, 2026Base award$493.5K
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Amgen USA Inc | 1 | $59.99M |
| 2 | Vericel Corporation | 1 | $34.88M |
| 3 | Spectral Md, Inc. | 1 | $31.67M |
| 4 | Ppd Development Lp | 6 | $31.12M |
| 5 | L3 Technologies, Inc. | 1 | $22.00M |
| 6 | Technical Resources International, Inc. | 6 | $21.80M |
| 7 | Abbott Laboratories | 1 | $21.01M |
| 8 | Paratek Pharmaceuticals, Inc | 1 | $17.47M |
| 9 | Ossium Health, Inc. | 1 | $12.39M |
| 10 | Rho Federal Systems Division Inc | 1 | $8.00M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50126F61020?
Contract 75A50126F61020 is a federal contract awarded to Glaxosmithkline, Llc by Department Of Health And Human Services on March 30, 2026 for $493,000 of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 0 times since the base award.
Who won contract 75A50126F61020?
Glaxosmithkline, Llc won contract 75A50126F61020 from Department Of Health And Human Services.
How much is contract 75A50126F61020 worth?
Contract 75A50126F61020 has obligated $493,000 to date.